摘要
目的探讨桂枝茯苓片联合头孢曲松治疗慢性盆腔炎的临床疗效。方法选取2020年2月—2023年1月陕西省中医医院收治的94例慢性盆腔炎患者,按随机数字表法将所有患者分为对照组和治疗组,每组各47例。所有患者于月经结束3d后给药。对照组静脉滴注注射用头孢曲松钠,将2.0g充分溶解于250m L生理盐水,1次/d。治疗组在对照组基础上口服桂枝茯苓片,3片/次,3次/d。两组疗程均为14 d。观察两组的临床疗效,比较治疗前后两组症状、体征、辅助检查积分及盆腔包块最大径、症状自评量表(SCL-90)评分、世界卫生组织生活质量测定简表(WHOQOL-BREF)评分和红细胞沉降率(ESR)、中性粒细胞与淋巴细胞比值(NLR)、C反应蛋白(CRP)水平。结果治疗后,治疗组总有效率为95.74%,显著高于对照组的82.98%(P<0.05)。治疗后,两组患者主症、次症、盆腔局部体征、辅助检查积分及其总积分均显著降低(P<0.05);且均以治疗组降低更显著(P<0.05)。治疗后,两组盆腔包块最大径和SCL-90评分均显著降低,而WHOQOLBREF评分均显著增加(P<0.05);且以上评分均以治疗组改善更显著(P<0.05)。治疗后,两组ESR、NLR、CRP水平均显著下降(P<0.05);治疗后,治疗组ESR、NLR、CRP水平均显著低于对照组(P<0.05)。结论桂枝茯苓片联合头孢曲松治疗慢性盆腔炎的整体效果确切,患者可有效获得症状体征的明显减轻,促进盆腔包块缩小及身心健康、生活质量的改善,调节机体血液流变学及炎症状态,值得临床推广应用。
Objective To explore the clinical efficacy of Guizhi Fuling Tablets combined with ceftriaxone in treatment of chronic pelvic inflammatory disease.Methods 94 Patients with chronic pelvic inflammatory disease treated in Shaanxi Provincial Hospital of Traditional Chinese Medicine from February 2020 to January 2023 were selected and divided into control group and treatment group according to random number table method,with 47 cases in each group.All patients were given the drug 3 d after the end of menstruation.Patients in the control group were iv administered with Ceftriaxone Sodium for injection,2.0 g was fully dissolve in 250 mL normal saline,once daily.Patients in the treatment group were po administered with Guizhi Fuling Tablets on the basis of the control group,3 tablets/time,three times daily.Patients in two groups were treated for 14 d.After treatment,the clinical efficacy was evaluated,symptoms,signs,auxiliary examination scores,maximum diameter of pelvic masses,Symptom Checklist 90(SCL-90)scores,World Health Organization Quality of Life Brief(WHO QOL BREF)scores,erythrocyte sedimentation rate(ESR),neutrophil to lymphocyte ratio(NLR),and C-reactive protein(CRP)levels between the two groups before and after treatment were compared.Results After treatment,the total effective rate of treatment group was 95.74%,which was significantly higher than that of control group(82.98%)(P<0.05).After treatment,the main disease,secondary disease,local pelvic signs,auxiliary examination scores and total scores were significantly decreased in both groups(P<0.05).The decrease was more significant in the treatment group(P<0.05).After treatment,the maximum diameter of pelvic mass and SCL-90 score were significantly decreased,while WHOQOL-BREF score was significantly increased in both groups(P<0.05).The improvement was more significant in the treatment group(P<0.05).After treatment,the levels of ESR,NLR and CRP in both groups were significantly decreased(P<0.05).After treatment,the levels of ESR,NLR and CRP in the treatment gro
作者
田颖
杨东艳
TIAN Ying;YANG Dong-yan(Department of Gynecology,Shaanxi Provincial Hospital of Traditional Chinese Medicine,Xi’an 710003,China)
出处
《现代药物与临床》
CAS
2023年第10期2563-2567,共5页
Drugs & Clinic
关键词
桂枝茯苓片
注射用头孢曲松钠
慢性盆腔炎
盆腔包块最大径
症状自评量表评分
红细胞沉降率
中性粒细胞与淋巴细胞比值
C反应蛋白
Guizhi Fuling Tablets
Ceftriaxone Sodium for injection
chronic pelvic inflammation disease
maximum diameter of pelvic mass
symptom self-rating scale score
erythrocyte sedimentation rate
neutrophil to lymphocyte ratio
CRP
